BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced inducement stock-option grants awarded Feb 10, 2026, to two employees hired in January 2026 under its 2025 Inducement Plan.

Rhea-AI Summary

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced inducement stock-option grants awarded Feb 10, 2026, to two employees hired in January 2026 under its 2025 Inducement Plan.

The awards total 65,350 non-qualified stock options at an exercise price of $10.84 per share, vesting 25% after one year then monthly over 36 months. Grants were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).

Argus Feb 12 session

-5.15% close to close Open Argus

Details

News Market Reaction – BBOT

In the Feb 12 session, BBOT declined 5.15%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.2% in the session following this news. A negative reaction despite the routine na...

Analysis

The stock moved -5.2% in the session following this news. A negative reaction despite the routine nature of this inducement grant would fit a pattern where non-clinical news sometimes triggers modest downside, as seen with prior events moving -1.25% and -1.95%. The announcement adds incremental stock options but does not change BBOT’s reported liquidity or pipeline data. Given stronger historical responses to clinical updates, any larger decline could reflect broader sentiment or positioning rather than the mechanics of this grant alone.

Key Figures

Current share price: $10.84 Inducement option shares: 65,350 shares Par value: $0.0001 per share +3 more

Current share price

$10.84

Closing price used as exercise price for inducement options

Inducement option shares

65,350 shares

Aggregate non-qualified stock options granted to new employees

Par value

$0.0001 per share

Par value of BBOT common stock underlying inducement options

Initial vesting tranche

1/4 of award

Vests on first anniversary of employee start date

Monthly vesting period

36 months

Equal monthly installments after first anniversary, subject to service

New hires covered

2 employees

Inducement awards for individuals hired in January 2026

Historical Context

5 past events · Latest: Jan 13

5 events

1. Jan 13

   Inducement grant

   24h Move

   +4.6%

   Stock option inducement grant for a new hire under 2025 Inducement Plan.

2. Jan 07

   Clinical data update

   24h Move

   +4.4%

   Preliminary Phase 1 safety and antitumor data across three RAS/PI3Kα programs.

3. Dec 16

   Conference presentation

   24h Move

   -1.3%

   Announcement of leadership presentation at the J.P. Morgan Healthcare Conference.

4. Dec 11

   Inducement grant

   24h Move

   -1.9%

   Inducement stock option grant for a November 2025 hire under Nasdaq Rule 5635(c)(4).

5. Dec 10

   Preclinical data

   24h Move

   +2.8%

   Late-breaking preclinical data on BBO-10203 as a first-in-class RAS:PI3Kα breaker.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, inducement grants, nasdaq listing rule 5635(c)(4)

3 terms

non-qualified stock options financial

"The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

inducement grants financial

"today announced it awarded inducement grants on February 10, 2026 under BBOT’s 2025 Inducement Plan"

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026.

The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $10.84 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BBOT announce about inducement grants on February 11, 2026?

BBOT announced the award of inducement option grants totaling 65,350 shares to two new hires. According to BridgeBio Oncology Therapeutics, the grants were made Feb 10, 2026 under the company’s 2025 Inducement Plan and approved by the compensation committee.

How many options and what exercise price were included in BBOT's inducement awards (BBOT)?

The inducement awards total 65,350 non-qualified stock options with an exercise price of $10.84 per share. According to BridgeBio Oncology Therapeutics, $10.84 equals the Nasdaq closing price on the effective grant date.

What is the vesting schedule for the BBOT inducement stock options?

The options vest 25% after one year, then in 36 equal monthly installments thereafter. According to BridgeBio Oncology Therapeutics, vesting is subject to each employee’s continued service through applicable vesting dates.

Under which plan were BBOT’s inducement awards granted and why?

The awards were granted under BBOT’s 2025 Inducement Plan as material inducements for new employment. According to BridgeBio Oncology Therapeutics, the plan was adopted by the board in October 2025 and used per Nasdaq Listing Rule 5635(c)(4).

Were BBOT’s inducement awards approved by independent directors or a committee?

Yes, the compensation committee approved the awards; the committee comprises solely independent directors. According to BridgeBio Oncology Therapeutics, the committee approved the grants as a material inducement to hire the two employees.

Do BBOT’s inducement grants come from shareholder-approved equity incentive plans?

No, the awards were granted outside the company’s stockholder-approved equity incentive plans. According to BridgeBio Oncology Therapeutics, the grants were made pursuant to the separate 2025 Inducement Plan adopted by the board.